Skip to main content
micro-community-banner
 
  • Saved

Commented on 's Post

STUDY OF EARLY RETINAL CHANGES IN PATIENTS WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS - PubMed

In patients with a very recent diagnosis of Type 2 Diabetes Mellitus, the retinal vessels diameters do not differ compared with individuals of similar age and blood pressure. However, the ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36027108/


Conclusions: In patients with a very recent diagnosis of Type 2 Diabetes Mellitus, the retinal vessels diameters do not differ compared with individuals of similar age and blood pressure. However, the AVR index correlates with age and nighttime BP, highlighting the important contribution of the latter in early target organ damage in this...

Show More Comments

  • December 29, 2022
    This reminds of what I learned in med school. Patients with type 1 DM should see their eye doctor every ~5 yrs for screening. For patient with type 2 DM, Show More
  • Saved

Commented on 's Post

The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study - PubMed

doi: 10.3390/medicines9090047. 1 Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Yufu City 879-5593, Oita, Japan. 2 Faculty of Medicine, Oita University, Yufu City 879-5593, Oita, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36135828/


Conclusions: These results suggest that the GLP1-RA semaglutide effectively reduces body adiposity while maintaining the MM in obese type 2 diabetic patients.

Show More Comments

  • October 26, 2022
    Interesting article that shows semaglutide effectively reduces body adiposity
  • Saved

Commented on 's Post

Care Endpoints in Adults With Type 2 Diabetes: Screening and Therapeutic Targets at a Canadian Tertiary Diabetes Care Centre

Although national diabetes guidelines recommend targets for various health parameters, studies have demonstrated a gap between recommendations and real-life practice. The objectives of the present study were to: 1) assess ..... see more

Source : https://www.canadianjournalofdiabetes.com/article/S1499-2671(22)00211-8/fulltext


Conclusions: Patients with T2DM at the MUHC receive guideline-based measurements of health parameters more frequently than at other institutions. Achievement of target values was closer to that seen by Canadian specialists than by primary care. Although further analyses are necessary to help implement effective strategies for improvement,...

Show More Comments

  • October 26, 2022
    Interesting article, but further analyses are necessary to help implement effective strategies for improvement
  • October 16, 2022
    Screening and counseling are important in preventing diabetes.
  • Saved

made a Post

Aldehyde Dehydrogenase 2 Activator Augments the Beneficial Effects of Empagliflozin in Mice with Diabetes-Associated HFpEF - PubMed

1 Division of Hypertension and Vascular Research, Department of Internal Medicine, Henry Ford Health System, Detroit, MI 48202, USA. 2 Department of Physiology, Wayne State University, Detroit, MI 48202, USA. ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36142350/


Conclusions: AMP-activated protein kinase (AMPK) pathways in ALDH2*2 mice with diabetes-associated HFpEF. This combination was even more effective than EMP alone. Our data indicate that ALDH2 activation along with the treatment of hypoglycemic agents may be a salient strategy to alleviate diabetes-associated HFpEF.

  • Saved

made a Post

The promising significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy

Objective: To explore the significance of liraglutide combined with dapagliflozin or empagliflozin in the prevention of early diabetic nephropathy (DN) and its effects on renal function indices. Methods: Three hundred ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452308/



Conclusions: Liraglutide combined with dapagliflozin or empagliflozin treatment can effectively reduce the levels of Tf, NGAL and TNF-α in patients with T2DM, and improve the renal function in terms of IGF-1, RBP, Hcy, BNP, UAER, UACR, L-FABP, showing high treatment safety.

  • Saved

made a Post

Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study - BMC Endocrine Disorders

Background IDegLira is a fixed-ratio combination of insulin degludec and liraglutide with proven efficacy against simpler regimens and non-inferiority against basal-bolus insulin therapy. However, the evaluation of its real-world effectiveness ..... see more

Source : https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-022-01139-8



Conclusions: Treatment with IDegLira over 18 months resulted in greater HbA1c reductions, weight loss versus gain, and a lower rate of hypoglycaemia versus ICT in people with type 2 diabetes.

  • Saved

Commented on 's Post

Influence of sodium-glucose Co-transporter 2 inhibitors on clinical and biochemical markers of dehydration during the Holy Ramadan

Excess glucose excretion and diuresis with sodium-glucose co-transporter 2 inhibitors may cause dehydration during Ramadan. * Clinical and biochemical markers of dehydration existed with sodium-glucose co-transporter 2 inhibitors during Ramadan. ..... see more

Source : https://www.sciencedirect.com/science/article/abs/pii/S187140212200220X?via=ihub


Conclusions: Significant clinical and biochemical markers of dehydration were noticed among users of SGLT2i during the Holy Ramadan.


Show More Comments

  • September 12, 2022
    Important study to detect the potential alteration of hydration status in adult Muslims with type 2 diabetes mellitus (T2D) who used SGLT2i during Ramadan.
  • Saved

made a Post

Renal Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus - PubMed

Type 2 diabetes mellitus (T2DM) is one of the main causes of mortality and morbidity worldwide. It leads to various long-term complications such as diabetic nephropathy. Diabetes nephropathy is the ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36045524/


Conclusions: Conclusion/Relevance: Sodium-glucose cotransporter 2 inhibitor of empagliflozin is a potent anti-hyperglycemic agent. In addition, it has been shown to have some pharmacologic potentials to provide renoprotective effects in patients with T2DM. In current study, we review the available clinical data on the potential renoprotective...

  • Saved

made a Post

Efficacy and Safety of Finerenone for Prevention of Cardiovascular Events in Type 2 Diabetes Mellitus with Chronic Kidney Disease: A Meta-analysis of Randomized Controlled Trials - PubMed

Only a few meta-analyses evaluated the effect of finerenone on cardiovascular events in type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). The main aim of this meta-analysis was ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36027585/


Conclusion: Overall, finerenone treatment showed a great benefit of reducing the risk of MACEs, all-cause mortality, myocardial infarction, and new-onset hypertension events in patients with T2DM and CKD.

  • Saved

Commented on 's Post

Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice

Semaglutide [glucagon-like peptide-1 receptor-agonist (GLP-1RA)] has shown nephroprotective effects in previous cardiovascular studies. However, its efficacy and safety in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9308087/


Conclusion/Relevance: In this real-world study, patients with T2D and CKD treated with subcutaneous semaglutide for 12 months significantly improved glycemic control and decreased weight. Albuminuria decreased by >50% in patients with macroalbuminuria. The administration of GLP-1RA in patients with T2D and CKD was safe and well tolerated.

Show More Comments

  • August 23, 2022
    Patients with T2D and CKD who develop macroalbuminuria have a greater risk of cardiovascular disease mortality than progression to ESKD
  • Saved

Commented on 's Post

Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors

Type 2 diabetes mellitus (T2DM) is a set of metabolic disorders specified by hyperglycemia as a result of abnormalities in insulin secretion or sensitivity. Chronic kidney disease (CKD) and cardiovascular ..... see more

Source : https://www.eurekaselect.com/article/125504


Relevance: Combinations such as empagliflozin and linagliptin, ertugliflozin and metolazone, dapagliflozin and sacubitril-valsartan and many more show promising results. Here, we have reviewed the ongoing and completed clinical trials, addressed current theories, and discussed necessary future research to explain the possible risks and...

Show More Comments

  • August 23, 2022
    Chronic kidney disease (CKD) and cardiovascular disease (CVD) are the widespread co-morbidities of T2DM and share risk factors for onset and progression
  • Saved

made a Post

Glucose-Lowering Treatment Patterns in Patients With Diabetic Kidney Disease

Objectives: Recent trials of glucose-lowering drugs (GLDs) have drawn attention to renal outcomes. Our goal was to understand how patients with diabetic kidney disease (DKD) are treated in general practices ..... see more

Source : https://www.ajmc.com/view/glucose-lowering-treatment-patterns-in-patients-with-diabetic-kidney-disease



Conclusions: Real-world treatment of DKD in the United States is suboptimal. Inappropriate use of some GLD classes, especially in advanced DKD stages, was found along with lower than expected use of modern agents that are considered safe and effective to treat glycemic outcomes. Efforts may be needed to improve understanding of safety,...

  • Saved

made a Post

Diabetes and Impaired Fracture Healing: A Narrative Review of Recent Literature - Current Osteoporosis Reports

Purpose of the Review Diabetes mellitus is a chronic metabolic disorder commonly encountered in orthopedic patients. Both type 1 and type 2 diabetes mellitus increase fracture risk and impair fracture ..... see more

Source : https://link.springer.com/article/10.1007/s11914-022-00740-z



Summary: The pathophysiology of impaired fracture healing in diabetic patients is complex. This review provides an update of the most recent findings on how key mediators of bone healing are affected in diabetes.

  • Saved

made a Post

Practical Considerations for Use of Insulin/Glucagon-Like Peptide 1 Receptor Agonist Combinations in Older Adults With Type 2 Diabetes - PubMed

Over 25% of adults ≥65 years of age have type 2 diabetes (T2D). Individualization of care is important in older adults with T2D, with treatment targets and therapeutic approaches informed ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35960944/



Conclusion/Relevance: Fixed-ratio combination injectable products offer unique benefits in older adults, including reduction of both fasting and postprandial glucose, low hypoglycemia risk, lack of weight gain, fewer gastrointestinal side effects, strong durability of effect, and the potential for medication regimen simplification.


  • Saved

made a Post

Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials - PubMed

Driven by price competition, the emergence of biosimilar insulins may help expand global access to current insulin analogues. To maximize the impact of the advantage for falling retail costs of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35818669/



Conclusions: Driven by price competition, the emergence of biosimilar insulins may help expand global access to current insulin analogues. To maximize the impact of the advantage for falling retail costs of biosimilar insulins compared with that of reference insulins, healthcare professionals and insulin users must gain further awareness and...

  • Saved

made a Post

Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes

AimsThis study aims to evaluate the effectiveness and tolerability of once-weekly glucagon-like peptide receptor agonists (OW GLP-1RAs) and to assess the clinical benefits of switching from one GLP-1RA to another ..... see more

Source : https://www.frontiersin.org/articles/10.3389/fendo.2022.892702/full



Conclusions: The effectiveness and tolerability of the OW GLP-1RAs in the real world were documented. Semaglutide was associated with the highest response without impact on safety. Clinical improvements were obtained even in switchers, especially in those switching to semaglutide.

  • Saved

made a Post

A Review of Oral Semaglutide Available Evidence: A New Era of Management of Diabetes with Peptide in a Pill Form

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have gained an important place in the management of diabetes management because of their exceptional glucose-lowering, weight lowering and cardiovascular (CV) benefits. Despite recommendations ..... see more

Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302409/


Relevance: The current review discusses the various aspects of oral semaglutide and its place in clinical practice.

  • Saved

made a Post

A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis - PubMed

Evidence is strongest for liraglutide compared to other licensed WLMs. The findings, particularly the inclusion of human trial data, provide evidence for liraglutide use in treating AIWG and OSP, which ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35863294/



Conclusion: Evidence is strongest for liraglutide compared to other licensed WLMs. The findings, particularly the inclusion of human trial data, provide evidence for liraglutide use in treating AIWG and OSP, which would better align psychiatric practice with non-psychiatric practices around obesity. The findings also identify continued...

  • Saved

made a Post

Change of renal function after short-term use of cardioprotective agents in patients with type 2 diabetes is not accurately assessed by the change of estimated glomerular filtration rate: an observational study - Diabetology & Metabolic Syndrome

Background After initiating cardioprotective agents, a fall of estimated glomerular filtration rate (eGFR) has been reported in several studies. Our goal was to evaluate the accuracy of change of Chronic ..... see more

Source : https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-022-00874-1



Conclusion: The agreement between eGFR by CKD-EPI and mGFR is modest and the change of renal function after short-term pharmacological intervention is not accurately and precisely reflected by the change of eGFR in patients with T2D in the early stage of their disease.


  • Saved

made a Post

Efficacy and safety of oral semaglutide in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study - PubMed

1 Division of Gastroenterology and Hepatology Nippon Medical School Tokyo Japan. 2 Core Research Facilities for Basic Science, Research Center for Medical Sciences The Jikei University School of Medicine Tokyo ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/35822119/


Conclusions: Oral semaglutide treatment in patients with NAFLD complicated by T2DM improved impaired liver function, hypertriglyceridemia, insulin resistance, and hepatic steatosis, as well as improving diabetic status and reducing body weight.